Total Payments
$2.1M
2024 Payments
$276,740
Companies
45
Transactions
3,770
Medicare Patients
7,543
Medicare Billing
$656,689
Payment Breakdown by Category
Other$1.4M (67.8%)
Travel$386,776 (18.7%)
Consulting$205,865 (10.0%)
Food & Beverage$65,496 (3.2%)
Research$6,434 (0.3%)
Education$189.18 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 606 | 67.7% |
| Travel and Lodging | $386,776 | 1,088 | 18.7% |
| Consulting Fee | $205,865 | 75 | 10.0% |
| Food and Beverage | $65,496 | 1,948 | 3.2% |
| Unspecified | $6,434 | 46 | 0.3% |
| Honoraria | $2,600 | 2 | 0.1% |
| Education | $189.18 | 5 | 0.0% |
Payments by Type
General
$2.1M
3,724 transactions
Research
$6,434
46 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $688,712 | 1,004 | $0 (2024) |
| Gilead Sciences, Inc. | $592,896 | 1,173 | $0 (2024) |
| Janssen Products, LP | $500,668 | 587 | $0 (2024) |
| Merck Sharp & Dohme LLC | $177,875 | 412 | $0 (2024) |
| EMD Serono, Inc. | $57,252 | 102 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $15,754 | 44 | $0 (2023) |
| Lilly USA, LLC | $11,356 | 32 | $0 (2024) |
| Napo Pharmaceuticals Inc | $8,212 | 23 | $0 (2022) |
| GlaxoSmithKline, LLC. | $3,903 | 24 | $0 (2023) |
| Theratechnologies Inc. | $3,407 | 33 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $276,740 | 425 | ViiV Healthcare Company ($136,731) |
| 2023 | $282,187 | 533 | ViiV Healthcare Company ($144,580) |
| 2022 | $321,684 | 490 | ViiV Healthcare Company ($132,508) |
| 2021 | $195,413 | 336 | ViiV Healthcare Company ($125,080) |
| 2020 | $144,902 | 268 | ViiV Healthcare Company ($58,063) |
| 2019 | $341,591 | 614 | Gilead Sciences, Inc. ($126,682) |
| 2018 | $275,138 | 550 | Gilead Sciences, Inc. ($114,232) |
| 2017 | $227,821 | 554 | Gilead Sciences Inc ($95,544) |
All Payment Transactions
3,770 individual payment records from CMS Open Payments — Page 1 of 151
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Gilead Sciences, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,715.00 | General |
| 12/23/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,170.00 | General |
| Category: HIV | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,030.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/17/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $29.06 | General |
| Category: HIV | ||||||
| 12/17/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/17/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Travel and Lodging | In-kind items and services | $12.06 | General |
| Category: HIV | ||||||
| 12/17/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $3.59 | General |
| Category: HIV | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.33 | General |
| 12/13/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $26.12 | General |
| Category: HIV | ||||||
| 12/11/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: HIV | ||||||
| 12/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.56 | General |
| 12/10/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $490.00 | General |
| Category: HIV | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug) | Food and Beverage | In-kind items and services | $29.55 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/10/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $25.23 | General |
| Category: HIV | ||||||
| 12/09/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Travel and Lodging | In-kind items and services | $60.06 | General |
| Category: HIV | ||||||
| 12/09/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $34.63 | General |
| Category: HIV | ||||||
| 12/09/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: HIV | ||||||
| 12/07/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: VIROLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $0.85 | General |
| Category: VIROLOGY | ||||||
| 12/04/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $626.34 | General |
| 12/04/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Travel and Lodging | In-kind items and services | $253.22 | General |
| Category: HIV | ||||||
| 12/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $121.85 | General |
| 12/04/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: HIV | ||||||
| 12/03/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL | GlaxoSmithKline, LLC. | $1,838 | 7 |
| A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | ViiV Healthcare Company | $1,401 | 9 |
| A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | GlaxoSmithKline, LLC. | $1,097 | 4 |
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $944.01 | 12 |
| Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ViiV Healthcare Company | $903.78 | 11 |
| A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ViiV Healthcare Company | $250.70 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 1,638 | 14,430 | $304,355 | $147,622 |
| 2022 | 32 | 1,638 | 23,467 | $307,525 | $155,016 |
| 2021 | 35 | 2,076 | 25,162 | $334,774 | $187,949 |
| 2020 | 35 | 2,191 | 33,141 | $347,729 | $166,102 |
Total Patients
7,543
Total Services
96,200
Medicare Billing
$656,689
Procedure Codes
130
All Medicare Procedures & Services
130 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 263 | 1,006 | $155,930 | $83,126 | 53.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 174 | 302 | $33,220 | $17,404 | 52.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 91 | 91 | $23,660 | $11,226 | 47.4% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 129 | 132 | $17,160 | $8,799 | 51.3% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 64 | 64 | $9,152 | $3,403 | 37.2% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 45 | 45 | $4,500 | $3,400 | 75.6% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 21 | 21 | $6,300 | $3,191 | 50.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 70 | 304 | $11,248 | $3,083 | 27.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 62 | 62 | $2,790 | $1,848 | 66.2% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 11 | 11 | $2,530 | $1,759 | 69.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 58 | 58 | $5,858 | $1,570 | 26.8% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2023 | 12 | 12 | $2,040 | $1,570 | 76.9% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 83 | 83 | $2,075 | $1,458 | 70.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $3,021 | $1,239 | 41.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 100 | 106 | $5,936 | $973.24 | 16.4% |
| 82947 | Blood glucose (sugar) level | Office | 2023 | 65 | 175 | $1,225 | $673.75 | 55.0% |
| 81002 | Urinalysis, manual test | Office | 2023 | 83 | 179 | $1,790 | $606.98 | 33.9% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 12 | 17 | $850.00 | $553.92 | 65.2% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 16 | 16 | $720.00 | $507.52 | 70.5% |
| 94640 | Inhalation treatment for airway obstruction or sputum production | Office | 2023 | 59 | 60 | $3,600 | $405.92 | 11.3% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 12 | 12 | $540.00 | $357.72 | 66.2% |
| J1071 | Injection, testosterone cypionate, 1 mg | Office | 2023 | 15 | 11,000 | $3,575 | $239.36 | 6.7% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 33 | 95 | $1,900 | $101.81 | 5.4% |
| 82272 | Stool analysis for blood, by peroxidase activity | Office | 2023 | 13 | 13 | $65.00 | $53.95 | 83.0% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 28 | 122 | $2,240 | $47.88 | 2.1% |
About Dr. Douglas Cunningham, D.O
Dr. Douglas Cunningham, D.O is a Geriatric Medicine healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104856475.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Douglas Cunningham, D.O has received a total of $2.1M in payments from pharmaceutical and medical device companies, with $276,740 received in 2024. These payments were reported across 3,770 transactions from 45 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M).
As a Medicare-enrolled provider, Cunningham has provided services to 7,543 Medicare beneficiaries, totaling 96,200 services with total Medicare billing of $656,689. Data is available for 4 years (2020–2023), covering 130 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Medicine
- Other Specialties Family Medicine
- Location Phoenix, AZ
- Active Since 07/03/2006
- Last Updated 04/13/2021
- Taxonomy Code 207QG0300X
- Entity Type Individual
- NPI Number 1104856475
Products in Payments
- CABENUVA (Biological) $262,662
- SYMTUZA (Drug) $250,678
- APRETUDE (Biological) $168,393
- Biktarvy (Drug) $143,202
- Descovy (Drug) $141,743
- Symtuza (Drug) $101,539
- ISENTRESS (Drug) $91,141
- DOVATO (Drug) $88,742
- Truvada (Drug) $80,385
- PREZCOBIX (Drug) $80,267
- RUKOBIA (Drug) $69,407
- Serostim (Drug) $37,930
- DELSTRIGO (Drug) $35,185
- TIVICAY (Drug) $26,658
- PIFELTRO (Drug) $25,568
- Genvoya (Drug) $25,220
- SEROSTIM (Drug) $10,058
- Mytesi (Drug) $8,212
- EDURANT (Drug) $6,635
- Odefsey (Drug) $4,411
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Geriatric Medicine Doctors in Phoenix
Dr. Lucia Gregorio, Md, MD
Geriatric Medicine — Payments: $13,523
Geriatric Medicine $13,523
Anil Nanda, Md, MD
Geriatric Medicine — Payments: $4,382
Geriatric Medicine $4,382
Allison Perrin, Md, MD
Geriatric Medicine — Payments: $1,855
Geriatric Medicine $1,855
Steven Perez, D.o, D.O
Geriatric Medicine — Payments: $649.27
Geriatric Medicine $649.27
Gary Salzman, Md, MD
Geriatric Medicine — Payments: $637.93
Geriatric Medicine $637.93
Kehart Flom Racoma
Geriatric Medicine — Payments: $373.98
Geriatric Medicine $373.98